MCRBMCRB looks in pennant, need to break above 8.45 also at 6.34 we have 34 ema on monthly we may see 11, 13 $ as target in next few month, Not an investment advice.
−0.8931USD
−113.72 MUSD
126.33 MUSD
119.44 M
About Seres Therapeutics, Inc.
Sector
Industry
CEO
Eric D. Shaff
Website
Headquarters
Cambridge
Employees (FY)
233
Founded
2010
ISIN
US81750R1023
FIGI
BBG0099X6859
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
$MCRB inside dayMCRB has a beautiful look. Been playing since the breakout and I think she has further to run. Inside days can be great reload situations. 90m float. Would love to see her fly tomorrow. :)
$MCRB - GAPFor reference in case you have not seen it. Here is the gap with no defined resistance. There will still be people selling or trying to short but I would love to see this filled by NYE.
$MCRB - 2 big reversal daysNot sure what is going on but it looked very similar before it mooned out of control. Not sure if it will happen but is a fun one to watch. I bought some Jan 22 15c for 0.23 for pure fun. It could go bust but it could also provide to be an exciting one to watch :) GLL
MCRB - Breaking out of triangle ?MCRB - Finally breaking out if this triangle ?
We can count a potential Leading Diagonal wave (i) on the 15min with a deep 3 waves corrective wave (ii).
A move below 24.36 would invalidate this view.
MCRB Triangle Symmetrical Top (bullish)I found this pattern at tickeron website with the following data:
STATUS = Confirmed
CURRENT CONFIDENCE = 88%
TARGET (EXIT) PRICE = 34.49 USD
BREAKOUT (ENTRY) PRICE = 28.53 USD
DISTANCE TO TARGET PRICE = 18.93%
EMERGED ON = Sep 10, 12:00 PM (EDT)
CONFIRMED ON = Sep 29, 10:10 AM (EDT)
WITH CONFIDENCE
Head & ShouldersOffering was at 21.50 & 20.85. Im expecting a 20% pullback before we see a bounce off the 20 support. Very overbought on high time frame 3 hr candles.
pssh im waiting until tomorrow :)its looking like about $15 to $16 a share tomorrow at the low before liftoff
Using Sine waves and Fibonacci Spirals to help find the low point on this current "high rise" still a bear market if you ask 2016 i think. . well at least until another one of them thar peaks coming up awful quickly :)
MCRB: Higher price rejection after gap upHigher price rejection after gap up
May try to fill it in the next few days,
If confirmed
PT1 = 17,97
PT2 = 4,73 for gap fill
Positive Topline Results from SER-109 Phase 3Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
– SER-109 met Phase 3 primary endpoint, showing a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared to placebo –
– SER-109 was well
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MCRB is 0.5842 USD — it has decreased by 6.87% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Seres Therapeutics, Inc. stocks are traded under the ticker MCRB.
Seres Therapeutics, Inc. is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
MCRB stock is 8.98% volatile and has beta coefficient of 0.58. Check out the list of the most volatile stocks — is Seres Therapeutics, Inc. there?
One year price forecast for Seres Therapeutics, Inc. has a max estimate of 15.0000 USD and a min estimate of 1.1000 USD.
MCRB earnings for the last quarter are −0.37 USD whereas the estimation was −0.50 USD which accounts for 26.21% surprise. Estimated earnings for the next quarter are −0.50 USD. See more details about Seres Therapeutics, Inc. earnings.
Seres Therapeutics, Inc. revenue for the last quarter amounts to 310.00 K USD despite the estimated figure of 1.50 M USD. In the next quarter revenue is expected to reach −155.00 K USD.
Yes, you can track Seres Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
MCRB stock has fallen by 15.88% compared to the previous week, the month change is a 23.13% fall, over the last year Seres Therapeutics, Inc. has showed a 90.26% decrease.
MCRB net income for the last quarter is −41.25 M USD, while the quarter before that showed −47.85 M USD of net income which accounts for 13.80% change. Track more Seres Therapeutics, Inc. financial stats to get the full picture.
Today Seres Therapeutics, Inc. has the market capitalization of 94.73 M, it has decreased by 3.99% over the last week.
No, MCRB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MCRB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Seres Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 233.00 employees. See our rating of the largest employees — is Seres Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Seres Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Seres Therapeutics, Inc. stock shows the sell signal. See more of Seres Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Seres Therapeutics, Inc. future price: according to them, MCRB price has a max estimate of 15.00 USD and a min estimate of 1.10 USD. Read a more detailed Seres Therapeutics, Inc. forecast: see what analysts think of Seres Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Seres Therapeutics, Inc. EBITDA is −92.17 M USD, and current EBITDA margin is −72.96%. See more stats in Seres Therapeutics, Inc. financial statements.